Slide 1: Q4 & FY 2025 Financial Results
Q4 & FY 2025 Financial Results Conference call | February 19, 2026 www.materialise.com | NASDAQ: MTLS | EURONEXT: MTLS
Slide 2: Safe Harbor Summary
Safe Harbor Summary This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections,
Slide 3: Agenda
Agenda • Q4 2025 Business Update Brigitte de Vet-Veithen • Q4 2025 Financial Highlights CEO • Q4 & FY 2025 Financial Results • 2026 Financial Guidance • Q&A Koen Berges CFO 3
Slide 4: Q4 2025 Business Update
Q4 2025 Business Update A stronger foundation to support our global ambitions Materialise Rings the Bell at Euronext Brussels • Complement our >10 years on Nasdaq with a European listing, to strengthen our global reach • Expand our investor base, reflecting our commitment to both US and European inv
Slide 5: Q4 2025 Business Update
Q4 2025 Business Update Medical - bringing personalized care to a broader market • Historic milestone - 700,000+ personalized devices delivered • 70,000+ patients touched with Materialise personalized solutions in 2025 • New Mimics release introduces case-based pricing model Software - evolving our
Slide 6: Q4 2025 – Financial Highlights
Q4 2025 – Financial Highlights • Revenue of 70.2 mEUR, representing an increase of 6.8% from Q4 2024 • Gross Profit of 40.8 mEUR, representing 58.1% of revenue • Adjusted EBIT of 4.0 mEUR, representing 5.7% of revenue • Net profit of 6.2 mEUR, representing 11 EUR-ct. per share • Net Cash position of
Slide 7: Consolidated Revenue
Q4 & Full Year 2025 Consolidated Revenue +0.3% Q4 2025 Revenue by Segment 266,765 267,633 16% Software Medical 31% Manufacturing +6.8% 65,680 70,164 53% Q4 2024 Q4 2025 FY 2024 FY 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Quarterly revenue of 70.2 mEUR, repres
Slide 8: Consolidated Adjusted EBITDA & EBIT
Q4 & Full Year 2025 Consolidated Adjusted EBITDA & EBIT +2.9% +8.8% 31,484 32,386 10,601 9,741 11.8% 12.1% 3.7% 4.0% 3,980 +121.2% 9,524 5.7% -1.8% 4,306 13,6% 6.6% Q4 2024 Q4 2025 FY 2024 FY 2025 -1,195 FY 2024 FY 2025 Adj. EBITDA Q4 2024 Q4 2025 Adj. EBIT [Data in kEUR unless noted otherwise. All
Slide 9: Medical Segment
Q4 & Full Year 2025 Medical Segment +15.4% +20.9% 134,239 42,983 116,358 35,562 32.0% 30.6% +36.4% +16.3% 37,016 13,024 31,837 9,547 35.2% 30.0% Q4 2024 Q4 2025 FY 2024 FY 2025 Q4 2024 Q4 2025 FY 2024 FY 2025 Revenue Adj. EBITDA [Data in kEUR unless noted otherwise. All numbers and percentages round
Slide 10: Software Segment
Q4 & Full Year 2025 Software Segment -6.8% -1.7% 43,899 5,562 5,469 40,907 13.4% 12.7% -1.3% +51.5% 1,701 11,124 10,974 1,123 15.5% 10.1% Q4 2024 Q4 2025 FY 2024 FY 2025 Q4 2024 Q4 2025 FY 2024 FY 2025 Revenue Adj. EBITDA [Data in kEUR unless noted otherwise. All numbers and percentages rounded] • Q
Slide 11: Manufacturing Segment
Q4 & Full Year 2025 Manufacturing Segment -13.2% 106,508 1,660 92,486 1.6% -9.9% -4.6% -13.2% -2.4% 22,719 22,174 -2,199 -2,989 Q4 2024 Q4 2025 FY 2024 FY 2025 Q4 2024 Q4 2025 -4,236 FY 2024 FY 2025 Revenue Adj. EBITDA [Data in kEUR unless noted otherwise. All numbers and percentages rounded] • Q4 2
Slide 12: Income Statement Highlights
Income Statement Highlights Q4 Full Year (in thousands of euros, except where indicated) Gross profit margin (in %) 2025 2024 2024 2024 58.1% 57.1% Revenue 70,164 65,680 267,633 266,765 55.4% 56.5% Cost of sales (29,373) (29,315) (114,684) (115,940) Gross profit 40,791 36,365 152,949 150,826 Researc
Slide 13: Other Financial Highlights
Other Financial Highlights Balance Sheet items 12/31/25 12/31/24 Cash flow from operations (in thousands of euros, except where indicated) 31,456 Cash and equivalents 133,918 102,304 25,319 Borrowings 63,113 41,284 6,218 5,273 Net Cash 70,805 61,020 Q4 2024 Q4 2025 FY 2024 FY 2025 Trade receivables
Slide 14: 2026 Financial Guidance
2026 Financial Guidance • Projecting our 3 segments to evolve at a different pace • Anticipating macro-economic headwinds in industrial market segments to persist • Continued investments in R&D while maintaining disciplined cost control • Expect 2026 consolidated revenue within 273 - 283 mEUR range
Slide 15: Adjusted EBIT/EBITDA Reconciliation
Appendix Adjusted EBIT/EBITDA Reconciliation Q4 Full Year [Data in kEUR unless noted otherwise. All numbers and percentages rounded] 2025 2024 2025 2024 Net profit/(loss) 6,206 2,907 7,716 13,406 Income taxes (695) (874) (429) 733 Financial expenses (1,777) (1,113) 5,616 2,969 Financial income (623)
Slide 16: Thank You
Thank You Contact: Investor Relations Materialise investors@materialise.com 16